A BILL 
To amend title XVIII of the Social Security Act to encourage 
the development and use of DISARM antimicrobial 
drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Developing an Innova-
4
tive Strategy for Antimicrobial Resistant Microorganisms 
5
Act of 2021’’ and as the ‘‘DISARM Act of 2021’’. 
6
23:53 Jul 22, 2021
H4127
2 
•HR 4127 IH
SEC. 2. ENCOURAGING THE DEVELOPMENT AND USE OF 
1
DISARM ANTIMICROBIAL DRUGS. 
2
(a) ADDITIONAL PAYMENT
FOR DISARM ANTI-
3
MICROBIAL DRUGS UNDER MEDICARE.— 
4
(1) IN GENERAL.—Section 1886(d)(5) of the 
5
Social Security Act (42 U.S.C. 1395ww(d)(5)) is 
6
amended by adding at the end the following new 
7
subparagraph: 
8
‘‘(N)(i)(I) Effective for discharges beginning on or 
9
after October 1, 2021, or such sooner date as specified 
10
by the Secretary, subject to subclause (II), the Secretary 
11
shall, after notice and opportunity for public comment (in 
12
the publications required by subsection (e)(5) for a fiscal 
13
year or otherwise), provide for an additional payment 
14
under a mechanism (separate from the mechanism estab-
15
lished under subparagraph (K)), with respect to such dis-
16
charges involving any DISARM antimicrobial drug, in an 
17
amount equal to— 
18
‘‘(aa) the amount payable under section 1847A 
19
for such drug during the calendar quarter in which 
20
the discharge occurred; or 
21
‘‘(bb) if no amount for such drug is determined 
22
under section 1847A, an amount to be determined 
23
by the Secretary in a manner similar to the manner 
24
in which payment amounts are determined under 
25
section 1847A based on information submitted by 
26
23:53 Jul 22, 2021
H4127
3 
•HR 4127 IH
the manufacturer or sponsor of such drug (as re-
1
quired under clause (v)). 
2
‘‘(II) In determining the amount payable under sec-
3
tion 1847A for purposes of items (aa) and (bb) of sub-
4
clause (I), subparagraphs (A) and (B) of subsection (b)(1) 
5
of such section shall be applied by substituting ‘102 per-
6
cent’ for ‘106 percent’ each place it appears and para-
7
graph (8)(B) of such section shall be applied by sub-
8
stituting ‘2 percent’ for ‘6 percent’. 
9
‘‘(ii) For purposes of this subparagraph, a DISARM 
10
antimicrobial drug is— 
11
‘‘(I) a drug— 
12
‘‘(aa) that— 
13
‘‘(AA) is approved by the Food and 
14
Drug Administration; 
15
‘‘(BB) is designated by the Food and 
16
Drug Administration as a qualified infec-
17
tious disease product under subsection (d) 
18
of section 505E of the Federal Food, 
19
Drug, and Cosmetic Act; and 
20
‘‘(CC) has received an extension of its 
21
exclusivity period pursuant to subsection 
22
(a) of such section; and 
23
23:53 Jul 22, 2021
H4127
4 
•HR 4127 IH
‘‘(bb) that has been designated by the Sec-
1
retary pursuant to the process established 
2
under clause (iv)(I)(bb); or 
3
‘‘(II) an antibacterial or antifungal biological 
4
product— 
5
‘‘(aa) that is licensed for use, or an anti-
6
bacterial or antifungal biological product for 
7
which an indication is first licensed for use, by 
8
the Food and Drug Administration on or after 
9
June 5, 2014, under section 351(a) of the Pub-
10
lic Health Service Act for human use to treat 
11
serious or life-threatening infections, as deter-
12
mined by the Food and Drug Administration, 
13
including those caused by, or likely to be caused 
14
by— 
15
‘‘(AA) an antibacterial or antifungal 
16
resistant pathogen, including novel or 
17
emerging infectious pathogens; or 
18
‘‘(BB) a qualifying pathogen (as de-
19
fined under section 505E(f) of the Federal 
20
Food, Drug, and Cosmetic Act); and 
21
‘‘(bb) has been designated by the Secretary 
22
pursuant to the process established under 
23
clause (iv)(I)(bb). 
24
23:53 Jul 22, 2021
H4127
5 
•HR 4127 IH
‘‘(iii) The mechanism established pursuant to clause 
1
(i) shall provide that the additional payment under clause 
2
(i) shall— 
3
‘‘(I) with respect to a discharge, only be made 
4
to a subsection (d) hospital that, as determined by 
5
the Secretary— 
6
‘‘(aa) is participating in the National 
7
Healthcare Safety Network Antimicrobial Use 
8
and Resistance Module of the Centers for Dis-
9
ease Control and Prevention; and 
10
‘‘(bb) has an antimicrobial stewardship 
11
program that aligns with the Core Elements of 
12
Hospital Antibiotic Stewardship Programs of 
13
the Centers for Disease Control and Prevention 
14
or the Antimicrobial Stewardship Standard set 
15
by the Joint Commission; and 
16
‘‘(II) apply to discharges occurring on or after 
17
October 1 of the year in which the drug or biological 
18
product is designated by the Secretary as a DIS-
19
ARM antimicrobial drug. 
20
For purposes of this clause, in the case of a similar report-
21
ing program described in item (aa), a subsection (d) hos-
22
pital shall be treated as participating in such a program 
23
if the entity maintaining such program identifies to the 
24
Secretary such hospital as so participating. 
25
23:53 Jul 22, 2021
H4127
6 
•HR 4127 IH
‘‘(iv)(I) The mechanism established pursuant to 
1
clause (i) shall provide for a process for— 
2
‘‘(aa) a manufacturer or sponsor of a drug or 
3
biological product to request the Secretary to des-
4
ignate the drug or biological product as a DISARM 
5
antimicrobial drug; and 
6
‘‘(bb) the designation (and removal of such des-
7
ignation) by the Secretary of drugs and biological 
8
products as DISARM antimicrobial drugs. 
9
‘‘(II) A designation of a drug or biological product 
10
as a DISARM antimicrobial drug may be revoked by the 
11
Secretary if the Secretary determines that— 
12
‘‘(aa) the drug or biological product no longer 
13
meets the requirements for a DISARM antimicrobial 
14
drug under clause (ii); 
15
‘‘(bb) the request for such designation con-
16
tained an untrue statement of material fact; or 
17
‘‘(cc) clinical or other information that was not 
18
available to the Secretary at the time such designa-
19
tion was made shows that— 
20
‘‘(AA) such drug or biological product is 
21
unsafe for use or not shown to be safe for use 
22
for individuals who are entitled to benefits 
23
under part A; or 
24
23:53 Jul 22, 2021
H4127
7 
•HR 4127 IH
‘‘(BB) an alternative to such drug or bio-
1
logical product is an advance that substantially 
2
improves the diagnosis or treatment of such in-
3
dividuals. 
4
‘‘(III) Not later than October 1, 2021, the Secretary 
5
shall publish in the Federal Register a list of the DISARM 
6
antimicrobial drugs designated under this subparagraph 
7
pursuant to the process established under subclause 
8
(I)(bb). The Secretary shall annually update such list. 
9
‘‘(v)(I) For purposes of determining additional pay-
10
ment amounts under clause (i), a manufacturer or sponsor 
11
of a drug or biological product that submits a request de-
12
scribed in clause (iv)(I)(aa) shall submit to the Secretary 
13
information described in section 1927(b)(3)(A)(iii). 
14
‘‘(II) The penalties for failure to provide timely infor-
15
mation under clause (i) of subparagraph (C) section 
16
1927(b)(3) and for providing false information under 
17
clause (ii) of such subparagraph shall apply to manufac-
18
turers and sponsors of a drug or biological product under 
19
this section with respect to information under subclause 
20
(I) in the same manner as such penalties apply to manu-
21
facturers under such clauses with respect to information 
22
under subparagraph (A) of such section. 
23
‘‘(vi)(I) The mechanism established pursuant to 
24
clause (i) shall provide that— 
25
23:53 Jul 22, 2021
H4127
8 
•HR 4127 IH
‘‘(aa) except as provided in item (bb), no addi-
1
tional payment shall be made under this subpara-
2
graph for discharges involving a DISARM anti-
3
microbial drug if any additional payments have been 
4
made for discharges involving such drug as a new 
5
medical service or technology under subparagraph 
6
(K); 
7
‘‘(bb) additional payments may be made under 
8
this subparagraph for discharges involving a DIS-
9
ARM antimicrobial drug if any additional payments 
10
have been made for discharges occurring prior to the 
11
date of enactment of this subparagraph involving 
12
such drug as a new medical service or technology 
13
under subparagraph (K); and 
14
‘‘(cc) no additional payment shall be made 
15
under subparagraph (K) for discharges involving a 
16
DISARM antimicrobial drug as a new medical serv-
17
ice or technology if any additional payments for dis-
18
charges involving such drug have been made under 
19
this subparagraph.’’. 
20
(2) 
CONFORMING
AMENDMENT.—Section 
21
1886(d)(5)(K)(ii)(III) of the Social Security Act (42 
22
U.S.C. 1395ww(d)(5)(K)(ii)(III)) is amended by 
23
striking ‘‘provide’’ and inserting ‘‘subject to sub-
24
paragraph (N)(vii), provide’’. 
25
23:53 Jul 22, 2021
H4127
9 
•HR 4127 IH
(b) AUTHORIZATION OF APPROPRIATIONS FOR THE 
1
CENTERS FOR DISEASE CONTROL AND PREVENTION.— 
2
There is authorized to be appropriated to the Centers for 
3
Disease Control and Prevention $500,000,000, to remain 
4
available until expended, to support establishment and im-
5
plementation of antimicrobial stewardship programs and 
6
data reporting capabilities to the Antimicrobial Use and 
7
Resistance option of the CDC National Healthcare Safety 
8
Network, especially in critical access hospitals, rural hos-
9
pitals, and community hospitals, to support detection, sur-
10
veillance, containment, and prevention of resistant patho-
11
gens in the United States and overseas. 
12
(c) STUDY AND REPORTS ON REMOVING BARRIERS 
13
TO
THE DEVELOPMENT
OF DISARM ANTIMICROBIAL 
14
DRUGS.— 
15
(1) STUDY.—The Comptroller General of the 
16
United States (in this subsection referred to as the 
17
‘‘Comptroller General’’) shall, in consultation with 
18
the Director of the National Institutes of Health, 
19
the Commissioner of Food and Drugs, the Adminis-
20
trator of the Centers for Medicare & Medicaid Serv-
21
ices, and the Director of the Centers for Disease 
22
Control and Prevention, conduct a study over a 5- 
23
year period of the barriers that prevent the develop-
24
ment of DISARM antimicrobial drugs (as defined in 
25
23:53 Jul 22, 2021
H4127
10 
•HR 4127 IH
section 1886(d)(5)(N)(ii) of the Social Security Act, 
1
as added by subsection (a)), including— 
2
(A) patient outcomes in conjunction with 
3
the use of DISARM drugs, including— 
4
(i) duration of stay in the intensive 
5
care unit; 
6
(ii) recidivism within 30 days; and 
7
(iii) measures of additional follow up 
8
care; 
9
(B) the effectiveness of antimicrobial stew-
10
ardship and surveillance programs, including— 
11
(i) changes in the percentage of hos-
12
pitals in the United States with an anti-
13
microbial stewardship program in place 
14
that aligns with the Core Elements of Hos-
15
pital Antibiotic Stewardship Programs, as 
16
outlined by the Centers for Disease Control 
17
and Prevention; 
18
(ii) changes in inpatient care of 
19
clostridioides difficile infection; and 
20
(iii) changes in inpatient rates of re-
21
sistance to key pathogens; and 
22
(C) considerations relating to Medicare 
23
payment reform, including— 
24
23:53 Jul 22, 2021
H4127
11 
•HR 4127 IH
(i) changes in the number of qualified 
1
antimicrobial products approved; 
2
(ii) changes in wholesale acquisition 
3
cost of individual qualified antimicrobial 
4
products over time; 
5
(iii) changes in year-over-year volume 
6
of individual qualified antimicrobial prod-
7
ucts sold; and 
8
(iv) the overall cost of qualified anti-
9
microbial products to the Medicare pro-
10
gram as a proportion of total Medicare 
11
part A spending. 
12
(2) REPORT.—Not later than 5 years after the 
13
date of the enactment of this Act, the Comptroller 
14
General shall submit to Congress a report containing 
15
the results of the study conducted under paragraph 
16
(1), together with recommendations for such legisla-
17
tion and administrative action as the Comptroller 
18
General determines appropriate. 
19
Æ 
23:53 Jul 22, 2021
H4127
